PTC Therapeutics, Inc.
PTC Therapeutics develops medicines for rare disorders globally. Products include Translarna, Emflaza, Upstaza, Tegsedi, Waylivra, and Evrysdi for conditions like Duchenne muscular dystrophy, SMA, and AADC deficiency. Pipeline products include Sepiapterin for phenylketonuria, PTC518 for Huntingtons disease, and vatiquinone/utreloxastat for Friedreich ataxia/Amyotrophic lateral sclerosis. The company distributes through third-party distributors. It has collaborations with various organizations.
Overview
Strengths
- Pricing power: gross margin has held between 93% and 95% over the last 5 years (latest 92.9%).
- Our discounted cash flow model points to 33% upside (target price 87.65 USD), and even our pessimistic growth scenario implies 15%: a margin of safety.
- Valued below its Biotechnology peers: P/E 7.8x vs. a median of 20.4x, P/FCF 13.0x vs. a median of 20.2x and EV/EBITDA 7.9x vs. a median of 15.6x.
- Consistent growth: revenue has compounded at 35.4% a year over 5 years, rising in 4 of them.
- ROIC of 29.8% beats 85% of its 128 Biotechnology peers (median 0.0%).
- EBITDA margin of 50.7% beats 89% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- Unreliable cash generation: free cash flow was negative in 5 of the last 6 years.
- Unstable profitability: operating margin ranged from -104% to 49% over the last 6 years, with operating losses in 5 of them.
- Shareholder dilution: the share count has grown by 3.7% a year over the last three years.
Key Financial Data